Hillmen P. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematol Meeting Rep [Internet]. 2009 May 28 [cited 2024 Nov. 23];1(2). Available from: https://www.pagepress.org/journals/hmr/article/view/226